2020
DOI: 10.3390/pharmaceutics12040300
|View full text |Cite
|
Sign up to set email alerts
|

Optimization of Thiolated Chitosan Nanoparticles for the Enhancement of in Vivo Hypoglycemic Efficacy of Sitagliptin in Streptozotocin-Induced Diabetic Rats

Abstract: Sitagliptin (SGN) is an antidiabetic drug used for treatment of diabetes mellitus type II. The objectives of this study were to formulate SGN in form of thiolated chitosan (TC) nanoparticles to enhance the mucoadhesion properties of SGN to the gastrointestinal tract, prolong drug release, decrease side effects, and enhance patient compliance. Seventeen batches of SGN-TC nanoparticles were designed by Box-Behnken design and prepared using the ionic gelation method using tripolyphosphate (TPP) as crosslinking ag… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 28 publications
(8 citation statements)
references
References 49 publications
(59 reference statements)
0
8
0
Order By: Relevance
“…A similar pattern for drug release was exhibited by thiolated chitosan NPs for the release of Sitagliptin as reported by Prabahar. 25…”
Section: In Vitro Release Studymentioning
confidence: 99%
“…A similar pattern for drug release was exhibited by thiolated chitosan NPs for the release of Sitagliptin as reported by Prabahar. 25…”
Section: In Vitro Release Studymentioning
confidence: 99%
“…The weak peak at 2580.44 cm −1 corresponds to SH, confirming the conjugation between the primary amine of CS and the thioglycolic acid CS-TGA. TC has three characteristic peaks at 1243 cm −1 , corresponding to the vibration of the C-S bond [ 29 , 52 ].…”
Section: Resultsmentioning
confidence: 99%
“…The amount of the non-capsulated drug in the supernatant was estimated spectrophotometrically at 269 nm, utilizing an ultraviolet spectrophotometer (Shimadzu, Yokohama, Japan). Different characterizations such as zeta potential (ZP), particle size as well as the polydispersity index (PDI) of the formulated nanoparticles were measured using a Zetasizer (Malvern Instruments Ltd., Malvern, UK) [ 40 , 41 ], while morphology of the surface of the nanoparticles was confirmed using transmission electron microscopy (TEM) (model JTEM-2100, Tokyo, Japan) [ 42 ]. Release of the drug from different trials was carried out using dialysis bag method [ 43 ] at simulated gastric fluid containing 0.1 N HCl and final pH equalsing 1.2 for 2 h and then substituted with phosphate buffer (pH = 6.8) for the next 10 h. Temperature was kept at 37 ± 1 °C, and drug was assayed spectrophotometrically at 269 nm (UV-visible spectrophotometer, Shimadzu, Yokohama, Japan) [ 44 ].…”
Section: Methodsmentioning
confidence: 99%